UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 気管支肺異形成症の病因および臨床的特徴 pathogenesis and clinical features of bronchopulmonary dysplasia
2. 気管支肺異形成症のマネージメント management of bronchopulmonary dysplasia
3. 気管支肺異形成症を有する乳児の転帰 outcome of infants with bronchopulmonary dysplasia
4. 気管支肺異形成症の肺の転帰 pulmonary outcomes of bronchopulmonary dysplasia
5. 気管支肺異形成症におけるステロイドの生後使用 postnatal use of glucocorticoids in bronchopulmonary dysplasia

English Journal

Executive functioning deficits in young adult survivors of bronchopulmonary dysplasia.

Gough A1, Linden MA, Spence D, Halliday HL, Patterson CC, McGarvey L.
Disability and rehabilitation.Disabil Rehabil.2015 Oct;37(21):1940-5. doi: 10.3109/09638288.2014.991451. Epub 2015 Jul 25.
PURPOSE: To assess long-term impairments of executive functioning in adult survivors of bronchopulmonary dysplasia (BPD).METHOD: Participants were assessed on measures of executive functioning, health-related quality of life (HRQoL) and social functioning. Survivors of BPD (n = 63; 34 males; mea
PMID 25495600

Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature.

Casciaro R, Naselli A, Cresta F, Ros M, Castagnola E, Minicucci L.
Journal of chemotherapy (Florence, Italy).J Chemother.2015 Oct;27(5):307-11. doi: 10.1179/1973947814Y.0000000194. Epub 2014 May 14.
OBJECTIVES: To review the data available in literature about nebulized amphotericin B (AMB) in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and to report our experience in the use of this drug, with a particular therapeutic scheme.CASE REPORT: We used nebul
PMID 24824366

Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.

Kool-Houweling LM1, Penning-van Beest FJ1, Bezemer ID1, van Lingen RA2, Herings RM1.
Acta paediatrica (Oslo, Norway : 1992).Acta Paediatr.2015 Sep;104(9):927-32. doi: 10.1111/apa.13081. Epub 2015 Jul 23.
AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart disease or bronchopulmonary dysplasia. We redressed
PMID 26073782

9-31. Bronchopulmonary foregut malformation (BPFM)の3症例(9.肺形成不全,手術,第23回日本小児呼吸器外科研究会)

渡邉文亮,徳井俊也,井谷英敏,笹野元,杉田貴紀,近藤茂人,谷川元昭,藤永一弥
気管支学 : 日本気管支研究会雑誌 34(4), 343-347, 2012-07-25
背景.アスペルギルス症は侵襲型(侵襲型肺アスペルギルス症),菌球型(肺アスペルギローマ),アレルギー型(アレルギー性気管支肺アスペルギルス症:ABPA)に大別される.今回気管支腔内に限局し,特異な画像ならびに病理所見を呈した菌球型アスペルギルス症の1例を経験したので報告する.症例.64歳,女性.肺癌検診において左下肺野に異常陰影を認め,当院を受診した.胸部CTでは左B^9bの拡張を認めた.経気管支 …
NAID 110009489908

高村恭子,大森さゆ,宮路尚子,置塩英美,倉辻言,市川知則,前山克博
日本未熟児新生児学会雑誌 = Journal of Japan Society for Premature and Newborn Medicine 24(2), 275-278, 2012-06-15
NAID 10030827364